Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product, DMX-200, for kidney diseases and for respiratory complications associated with COVID-19. Dimerix has three Phase 3 clinical programs with near term value propositions 1) Global Phase 3 REMAP-CAP study in at least 200 hospitalised COVID-19 patients with respiratory pneumonia in Europe and UK 2) Multi-national Phase 3 CLARITY 2.0 study in at least 600 COVID-19 patients with respiratory complications in India 3) Global Phase 3 study in Focal Segmental Glomerulosclerosis (FSGS) patients, which is a rare kidney disease, following positive Phase 2 data in 2020 and for which Dimerix has been granted Orphan Drug Designation by the FDA and EMA Dimerix also has longer term programs in Diabetic Kidney Disease and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).
